Merck Sharp & Dohme Limited (MSD) markets PROPECIA (finasteride 1 mg)
The licensed indication for PROPECIA in the UK is for the treatment of men with male pattern hair loss (androgenetic alopecia) to increase hair growth and prevent further hair loss.
Male pattern hair loss is a significant disorder with a defined pathology that is easily recognisable in adult men and has important consequences – usually social. It is clear from the clinical data, and experts agree, that the treatment is effective and can increase scalp hair count and density in a cosmetically significant manner.
PROPECIA is not indicated for women and children.
MSD is delighted to have received marketing authorisation for PROPECIA and confirmation that the regulatory authorities find that PROPECIA meets the agency’s high standards of safety, quality and efficacy.
In all other markets in which it is available, PROPECIA is prescribed privately and is not reimbursed by national governments or paid for out of the public purse. MSD’s preference in the UK is for private prescribing of which Schedule 10 of the NHS (General Medical Services) Regulations 1992* is one option.